Companies: 10,795·Total market cap: $144.5T

Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc.

TARSNASDAQHealthcare● Active

$59.39

+$0.11(+0.19%)

Market Cap$2.6B

P/E Ratio—

52W High$85.25

52W Low$38.51

Avg Volume623K

Open$59.43

Beta0.51

Net Income Financials Revenue

Tarsus Pharmaceuticals, Inc. (TARS) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

TARS · net income · updated Jun 8, 2026

Core profitability metrics

TARS · net income · margin · TTM · CAGR

Net income was −$66.4M for FY2025 (fiscal year ending 2025-12-31), up 42.5% year-over-year. Net profit margin was -14.7%.

FY2025 Net Income−$66.4M▲ +42.5% YoY

Trailing 12M (TTM)−$48.3Mtrailing 4 quarters sum

Net Profit Margin-14.7%−$66.4M ÷ $451.4M

YoY Change+42.5%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 8, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %

▸ FMP /income-statement · Annual · TARS net income history · TARS profit margin

Annual net income data

TARS · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025Loss−$66.4M▲ +42.5%-14.7%$451.4M

FY2024Loss−$115.6M▲ +15.0%-63.2%$183.0M

FY2023Loss−$135.9M▼ 118.9%-778.9%$17.4M

FY2022Loss−$62.1M▼ 349.1%-240.5%$25.8M

FY2021Loss−$13.8M▲ +48.4%-24.3%$57.0M

Net income vs peers (Healthcare)

TARS vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

#1

Tarsus Pharmaceuticals, Inc.YOU

TARS

−$66.4M+42.5%-14.7%

Loss

Johnson & Johnson

$26.80B+90.6%28.5%

Eli Lilly and Company

$20.64B+94.9%31.7%

UnitedHealth Group Incorporated

$12.06B-16.3%2.7%

$4.23B-1.2%6.9%

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Tarsus Pharmaceuticals, Inc. (TARS) reported net income of −$66.4M for FY2025 (fiscal year ending 2025-12-31), up 42.5% year-over-year. The net profit margin was -14.7% — meaning the company kept $-0.15 of every dollar of revenue as profit.

Tarsus Pharmaceuticals, Inc. has not yet achieved annual profitability based on available data (8 fiscal years). The company has reported net losses across all available periods.

Tarsus Pharmaceuticals, Inc.'s net profit margin was -14.7% for FY2025, based on the latest annual results.

Investors sometimes search for "Tarsus Pharmaceuticals, Inc. net worth" — the company's market capitalization is a separate figure from TARS net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

TARS net income · 4 questions

Tarsus Pharmaceuticals, Inc. is not currently profitable on an annual basis. The company reported a net loss of $66.4M for FY2025.

is TARS profitabledoes TARS make a profitTARS profitabilityTARS profitable company

▸ Source: FMP /income-statement · GAAP · Tarsus Pharmaceuticals, Inc. · Tarsus Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026